Clinical trial

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis - Pilot

Name
PLACER-2021C3-24476
Description
Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone.
Trial arms
Trial start
2023-11-21
Estimated PCD
2024-05-01
Trial end
2024-05-01
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Amoxicillin/clavulanate
Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
Arms:
antibiotic, antibiotic plus intranasal corticosteroid
Other names:
Augmentin
Placebo antibiotic
Placebo antibiotic, oral, twice daily for 7 days
Arms:
placebo antibiotic, placebo antibiotic plus intranasal corticosteroid
Other names:
Inactive, Control
Budesonide nasal spray
Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
Arms:
antibiotic plus intranasal corticosteroid, placebo antibiotic plus intranasal corticosteroid
Other names:
Rhinocort
C-reactive protein
Measurement of C-reactive protein level in capillary blood
Arms:
antibiotic, antibiotic plus intranasal corticosteroid, placebo antibiotic, placebo antibiotic plus intranasal corticosteroid
Other names:
CRP
Mid-turbinate swab (optional)
Optional collection of mid-turbinate nasal swab sample
Arms:
antibiotic, antibiotic plus intranasal corticosteroid, placebo antibiotic, placebo antibiotic plus intranasal corticosteroid
Other names:
Mid-nasal swab
Size
144
Primary endpoint
Improvement of symptoms
Baseline and 3 days post-randomization
Eligibility criteria
Inclusion Criteria: ○ 18-65 years old; AND experiencing ongoing symptoms or signs that suggest an acute sinus infection lasting for 1-21 days, without any signs clinical improvement Exclusion Criteria: * allergy or intolerance to penicillin * received systemic antibiotic therapy in the past 4 weeks * prior sinus surgery * complications of sinusitis (facial edema (swelling), cellulitis), or orbital, meningeal or cerebral signs) * health care clinician determined IV (intravenous) antibiotics or hospital admission are required * pregnancy or breastfeeding * presence of a comorbidity or medication that may impair a patient's immune response as determined by a health care clinician * unable to read, speak or understand English or Spanish * hospitalization in past 5 days * unable or unwilling to provide informed consent or comply with study protocol requirements * fever \>39°C or 102°F; OR * taking intranasal corticosteroids (INCS) regularly in the past two weeks
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'FACTORIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 144, 'type': 'ESTIMATED'}}
Updated at
2024-05-23

1 organization

3 products

1 indication

Organization
Daniel Merenstein
Indication
Sinusitis
Product
Budesonide